Luke Hansen, M.D., M.H.S., and chief medical officer of Arcadia, a healthcare data analytics company, said that achieving value-based care will need to be a multipronged approach with commercial purchasers and state Medicaid programs playing a prominent role.
The future of value-based care under the current Trump administration depends on a variety of factors, according to Luke Hansen, M.D., M.H.S., and chief medical officer of Arcadia.
Luke Hansen, M.D., M.H.S.
“Changes in administration are an opportunity to reexamine the success of previous programs,” Hansen said in a video interview with Managed Healthcare Executive. “My take on it is that it's going to take a recipe, it's going to take a mix, because you need incentives for PCPs, but you also need additional incentives for specialists that haven't existed yet, and you need incentives for other kinds of key stakeholders in the industry.”
He explained his point further by using a multihospital health system as an example.
“So, a multihospital health system, have they really been incentivized to chase total cost of care? And how can we build a program that will do that?” “Because the Medical Shared Savings Programs and the other Accountable Care Organizations iterations since then, there are savings that absolutely accrue to Medicare, but when those savings are taken out of the revenue stream of the sponsor organization, there's a tension there that I wish we could get past. How can we set up a system where all the stakeholders benefit through more efficient care?”
Hansen also mentioned the important role states play in the Medicaid program.
If [states’] overall revenue availability for Medicaid starts to shrink, the states are going to have to be creative, and that might be a driver of value-based care,” Hansen said. “Hopefully the states can be stewards in the Medicaid program with flexibilities that they didn't have before.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
A Conversation with Jeremiah Johnson, Executive Director of PrEP4All
July 25th 2025Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the importance of preexposure anaphylaxis and why he’s hesitant to jump on the Lenacapavir breakthrough bandwagon.
Read More
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More